Different types of movement disorders are difficult to distinguish due to many patients experiencing similar symptoms. Stephen Stahl, MD, discusses the differences between movement disorders, how they might…
PRX002 is an investigational antibody against α-synuclein as a disease-modifying therapy that stops the misfolding of α-synuclein and/or the spread of its aggregates in the brain.
While there are not yet any standardized criteria for selecting candidates for deep brain stimulation (DBS) therapy, Kelvin L. Chou, MD, Co-Director of the STIM (Surgical Therapies Improving…
As patients begin displaying symptoms of Parkinson’s disease, it becomes increasingly difficult for them to express themselves verbally, and they may even become overwhelmed in loud social situations.…
Some of the globe’s leading minds in medical research gathered at this year’s World Stem Cell Summit to discuss the recent developments, breakthroughs, and challenges that have arisen…
Results from a retrospective study in Lancet Neurology reveal that high concentrations of neurofilament light proteins (NfLs) in blood plasma of HTT gene mutation carriers can predict clinical…
